10-Q/A: Revelation Biosciences Files Amended Quarterly Report Due to Certification Omission

Revelation Biosciences has filed an amendment to its original quarterly report to include previously omitted language in its certifications.

Summary

• Revelation Biosciences filed an amendment to its original quarterly report on Form 10-Q for the period ended June 30, 2024.
• The amendment was made solely to include revised language in the certifications of the principal executive and financial officers.
• The company's financial position includes cash and cash equivalents of $12.1 million and a total stockholders equity of $1.1 million as of June 30, 2024.
• The company reported a net loss of $11.1 million for the six months ended June 30, 2024.
• The company has an accumulated deficit of $36.5 million as of June 30, 2024.
• The company's operating expenses totaled $4.4 million for the six months ended June 30, 2024.
• The company has ongoing programs to evaluate its proprietary formulation Gemini for various treatments and preventions.
• The company's current cash balance is not expected to be sufficient to sustain operations within one year, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, an accumulated deficit, and a going concern issue, which are major negatives. While the company is seeking additional funding, the overall sentiment is negative due to the financial instability and uncertainty.

Positives

• The company has $12.1 million in cash and cash equivalents.
• The company is actively pursuing additional funding to continue operations.

Negatives

• The company has incurred a net loss of $11.1 million for the six months ended June 30, 2024.
• The company has an accumulated deficit of $36.5 million.
• The company's current cash balance is not expected to be sufficient to sustain operations within one year.
• The company has never generated revenue and does not expect to generate revenue from product sales for several years.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash reserves.
• The company may not be able to obtain financing on acceptable terms, or at all.
• Failure to obtain funding could lead to delays or elimination of research and development programs.
• The company is subject to claims and litigation arising in the ordinary course of business, including a recent judgment against them for $7.3 million plus $0.2 million in costs.
• The company's financial results will reflect the volatility in estimates and assumptions related to liability-classified financial instruments.

Future Outlook

The company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future. The company does not anticipate generating revenue from product sales for at least several years, if ever. The company plans to seek additional funding through public or private equity or debt financings.

Management Comments

• The company's management has stated that the amendment was made solely to include revised language in the certifications of the principal executive and financial officers.
• Management acknowledges that the company's current cash balance is not expected to be sufficient to sustain operations within one year.

Industry Context

The company operates in the biopharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on trained immunity is a relatively new approach in the industry, and its success will depend on the clinical trial results and regulatory approvals of its product candidates.

Comparison to Industry Standards

• The company's financial position is weak compared to established biopharmaceutical companies, which typically have more substantial cash reserves and revenue streams.
• The company's reliance on external funding is common for early-stage biopharmaceutical companies, but the uncertainty of securing funding poses a significant risk.
• The company's research and development expenses are typical for a clinical-stage company, but the lack of revenue generation makes it vulnerable to financial instability.
• The company's net loss and accumulated deficit are significant, indicating the challenges of developing and commercializing new drugs.
• Comparable companies in the early stages of development often face similar challenges with cash flow and funding, but the specific financial metrics of each company vary widely based on their stage of development, technology, and market focus.

Legal Proceedings

• LifeSci Capital LLC filed an action against the Company seeking damages for unpaid banking and advisory fees.
• The District Court judge entered an order adopting the Magistrate Judges report and granted the summary judgment and issued a judgment, including interest, totaling $7.3 million.
• LifeSci filed a motion for reimbursement of costs in the amount of $0.2 million.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution from future capital raises.
• Employees may be impacted by potential delays or reductions in research and development programs.
• Customers and suppliers may be affected by the company's ability to continue operations and develop its product candidates.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will seek additional funding through public or private equity or debt financings.
• The company will continue to develop its product candidates, GEM-AKI, GEM-CKD, and GEM-PSI.
• The company will continue to monitor and manage its cash flow and operating expenses.

Key Dates

Keywords

biopharmaceutical, clinical-stage, trained immunity, GEM-AKI, GEM-CKD, GEM-PSI, public offering, warrants, reverse stock split, going concern, financial statements, research and development, operating expenses, net loss, stock-based compensation